Neşe Demirtürk1, Bilgehan Aygen2, İlhami Çelik3, Reşit Mıstık4, Sıla Akhan5, Şener Barut6, Onur Ural7, Ayşe Batırel8, Funda Şimşek9, Gülden Ersöz10, Dilara İnan11, Sami Kınıklı12, Nesrin Türker13, Hüseyin Bilgin14, Yunus Gürbüz15, Necla Tülek16, Hüseyin Tarakçı17, Orhan Yıldız2, Emine Türkoğlu1, Deniz Kamalak Güzel3, Sümeyra Şimşek18, Nazan Tuna19, Nazlım Aktuğ Demir7, Atahan Çağatay20, Rıza Aytaç Çetinkaya21, Faruk Karakeçili22, İsmail Necati Hakyemez23, Günay Tuncer Ertem12, Bahar Örmen13, Pınar Korkmaz24, Uluhan Yıldız14, Ziya Kuruüzüm25, Alper Şener26, Selcan Arslan Özel27, Sinan Öztürk28, Kaya Suer29, Mustafa Kemal Çelen30, Petek Konya1, Ali Asan31, Neşe Saltoğlu32, Nurhan Doğan33. 1. Department of Infectious Disease and Clinical Microbiology, Afyon Saglik Bilimleri University Medical Faculty, Afyonkarahisar, Turkey. 2. Department of Infectious Disease and Clinical Microbiology, Erciyes University Medical Faculty, Kayseri, Turkey. 3. Department of Infectious Diseases and Clinical Microbiology, Kayseri Education and Research Hospital, Saglik Bilimleri University, Kayseri, Turkey. 4. Infectious Disease Clinic, Medicana Hospital, Bursa, Turkey. 5. Department of Infectious Disease and Clinical Microbiology, Kocaeli University Medical Faculty, Kocaeli, Turkey. 6. Department of Infectious Disease and Clinical Microbiology, Gaziosmanpasa University Medical Faculty, Tokat, Turkey. 7. Department of Infectious Disease and Clinical Microbiology, Selcuk University Medical Faculty, Konya, Turkey. 8. Department of Infectious Diseases and Clinical Microbiology, Kartal Lütfi Kırdar Education and Research Hospital, Saglik Bilimleri University, İstanbul, Turkey. 9. Department of Infectious Diseases and Clinical Microbiology, Ok Meydanı Education and Research Hospital, Saglik Bilimleri University, İstanbul, Turkey. 10. Department of Infectious Disease and Clinical Microbiology, Mersin University Medical Faculty, Mersin, Turkey. 11. Department of Infectious Disease and Clinical Microbiology, Akdeniz University Medical Faculty, Antalya, Turkey. 12. Department of Infectious Diseases and Clinical Microbiology, Ankara Education and Research Hospital, Saglik Bilimleri University, Ankara, Turkey. 13. Department of Infectious Disease and Clinical Microbiology, Atatürk Education and Research Hospital, Katip Çelebi University, İzmir, Turkey. 14. Department of Infectious Disease and Clinical Microbiology, Marmara University Medical Faculty, İstanbul, Turkey. 15. Department of Infectious Disease and Clinical Microbiology, Dışkapı Education and Research Hospital University Medical Faculty, Saglik Bilimleri University, Antalya, Turkey. 16. Department of Infectious Disease and Clinical Microbiology, Atılım University Medical Faculty, Ankara, Turkey. 17. Department of Infectious Diseases and Clinical Microbiology, Eşrefpaşa Education and Research Hospital, Saglik Bilimleri University, İzmir, Turkey. 18. Department of Infectious Disease and Clinical Microbiology, Uludağ University Medical Faculty, Bursa, Turkey. 19. Department of Infectious Diseases and Clinical Microbiology, Sakarya Education and Research Hospital, Saglik Bilimleri University, Sakarya, Turkey. 20. Department of Infectious Disease and Clinical Microbiology, İstanbul University İstanbul Medical Faculty, İstanbul, Turkey. 21. Department of Infectious Diseases and Clinical Microbiology, Sultan Abdülhamid Han Education and Research Hospital, Saglik Bilimleri University, İstanbul, Turkey. 22. Department of Infectious Diseases and Clinical Microbiology, Erzincan University of Faculty of Medicine, Erzincan, Turkey. 23. Department of Infectious Diseases and Clinical Microbiology, Bezmiâlem University of Faculty of Medicine, İstanbul, Turkey. 24. Department of Infectious Diseases and Clinical Microbiology, Kütahya Health Sciences University Faculty of Medicine, Kütahya, Turkey. 25. Department of Infectious Disease and Clinical Microbiology, Dokuz Eylül University Faculty, İzmir, Turkey. 26. Department of Infectious Diseases and Clinical Microbiology, Çanakkale Onsekiz Mart University Faculty of Medicine, Çanakkale, Turkey. 27. Department of Infectious Diseases and Clinical Microbiology, Kocaeli Training and Research Hospital, Saglik Bilimleri University, Kocaeli, Turkey. 28. Department of Infectious Diseases and Clinical Microbiology, Ümraniye Education and Research Hospital, Saglik Bilimleri University, Kocaeli, Turkey. 29. Department of Infectious Diseases and Clinical Microbiology, Yakın Doğu University of Faculty of Medicine, Nicosia, Turkey. 30. Department of Infectious Diseases and Clinical Microbiology, Dicle University Faculty of Medicine, Diyarbakır, Turkey. 31. Department of Infectious Diseases and Clinical Microbiology, Bursa Yüksek İhtisas Training and Research Hospital, Saglik Bilimleri University, Bursa, Turkey. 32. Department of Infectious Diseases and Clinical Microbiology, İstanbul University of Cerrahpaşa Faculty of Medicine, İstanbul, Turkey. 33. Department of Biostatistics and Medical Informatics, Afyon Saglik Bilimleri University Medical Faculty, Afyonkarahisar, Turkey.
Abstract
BACKGROUND: In this study, we aimed to investigate the efficacy and safety of sofosbuvir-based therapies in the treatment of chronic hepatitis C in real-world clinical practice. METHODS: Data from patients with chronic hepatitis C treated with SOF/LDV ± RBV or SOF/RBV in 31 centers across Turkey between April 1, 2017, and August 31, 2018, were recorded in a nationwide database among infectious disease specialists. Demographics, clinical, and virological outcomes were analyzed. RESULTS: A total of 552 patients were included in the study. The mean age of the patients was 51.28 ± 14.2, and 293 (55.8%) were female. The majority had HCV genotype 1b infection (65%), 75.04% of the patients underwent treatment, and non-cirrhosis was present at baseline in 381 patients (72.6%). SOF/LDV ± RBV treatment was given to 477 patients and 48 patients received SOF/RBV according to HCV genotype. The total SVR12 rate was 99% in all patients. Five patients experienced disease relapse during the study and all of them were genotype 2. In patients infected with HCV GT2, SVR12 was 77.3%. SVR was 100% in all patients infected with other HCV genotypes. All treatments were well tolerated by patients without causing severe adverse events. Side effects and side effects-associated treatment discontinuation rates were 28.2% and 0.4%, respectively. Weakness (13.7%) was the common side effect. CONCLUSION: The present real-world data of 525 patients with HCV genotypes 1, 1a, 1b, 3, 4, and 5 who underwent SOF/LDV ± RBV treatment in Turkey demonstrated a high efficacy and safety profile. HCV GT2 patients should be treated with more efficacious treatment.
BACKGROUND: In this study, we aimed to investigate the efficacy and safety of sofosbuvir-based therapies in the treatment of chronic hepatitis C in real-world clinical practice. METHODS: Data from patients with chronic hepatitis C treated with SOF/LDV ± RBV or SOF/RBV in 31 centers across Turkey between April 1, 2017, and August 31, 2018, were recorded in a nationwide database among infectious disease specialists. Demographics, clinical, and virological outcomes were analyzed. RESULTS: A total of 552 patients were included in the study. The mean age of the patients was 51.28 ± 14.2, and 293 (55.8%) were female. The majority had HCV genotype 1b infection (65%), 75.04% of the patients underwent treatment, and non-cirrhosis was present at baseline in 381 patients (72.6%). SOF/LDV ± RBV treatment was given to 477 patients and 48 patients received SOF/RBV according to HCV genotype. The total SVR12 rate was 99% in all patients. Five patients experienced disease relapse during the study and all of them were genotype 2. In patients infected with HCV GT2, SVR12 was 77.3%. SVR was 100% in all patients infected with other HCV genotypes. All treatments were well tolerated by patients without causing severe adverse events. Side effects and side effects-associated treatment discontinuation rates were 28.2% and 0.4%, respectively. Weakness (13.7%) was the common side effect. CONCLUSION: The present real-world data of 525 patients with HCV genotypes 1, 1a, 1b, 3, 4, and 5 who underwent SOF/LDV ± RBV treatment in Turkey demonstrated a high efficacy and safety profile. HCV GT2 patients should be treated with more efficacious treatment.
Authors: S H Ahn; Y S Lim; K S Lee; S W Paik; Y J Lee; S H Jeong; J H Kim; S K Yoon; H J Yim; W Y Tak; S Y Han; J C Yang; H Mo; A Mathias; L Han; S J Knox; D M Brainard; Y J Kim; K S Byun; Y S Kim; J Heo; K H Han Journal: J Viral Hepat Date: 2016-02-10 Impact factor: 3.728
Authors: Javier Crespo; Jose Luis Calleja; Inmaculada Fernández; Begoña Sacristan; Belén Ruiz-Antorán; Javier Ampuero; Marta Hernández-Conde; Javier García-Samaniego; Francisco Gea; Maria Buti; Joaquin Cabezas; Sabela Lens; Rosa Maria Morillas; Jose Ramon Salcines; Juan Manuel Pascasio; Juan Turnes; Federico Sáez-Royuela; Juan Arenas; Diego Rincón; Martin Prieto; Francisco Jorquera; Juan Jose Sanchez Ruano; Carmen A Navascués; Esther Molina; Adolfo Gallego Moya; José Maria Moreno-Planas Journal: Clin Gastroenterol Hepatol Date: 2017-02-24 Impact factor: 11.382
Authors: Lisa I Backus; Pamela S Belperio; Troy A Shahoumian; Timothy P Loomis; Larry A Mole Journal: Hepatology Date: 2016-06-07 Impact factor: 17.425